{"title":"2022年1月至7月印度尼西亚COVID-19疫苗接种状况与COVID-19确诊患者严重程度的关系","authors":"Eka Desi Purwanti, Sudarto Ronoatmojo","doi":"10.26553/jikm.2023.14.1.13-26","DOIUrl":null,"url":null,"abstract":"The COVID-19 vaccine is known to prevent infection, disease severity, and death from COVID-19. The emergence of a new variant of the SARS-CoV-2 would have an impact on the vaccine's effectiveness. This study aims to examine the association between COVID-19 vaccination status and the severity of COVID-19 symptoms during the dominating period of the Omicron variant. This is a cross-sectional study using secondary data from confirmed COVID-19 patients who were reported in the Ministry of Health's Online Hospital System for the period January–July 2022. Using logistic regression analysis, we calculated the adjusted odds ratio (AOR) of the association between vaccination status and the severity of COVID-19 symptoms. A total of 221,673 confirmed COVID-19 patient data were analyzed. The proportion of patients with severe-critical symptoms is 6.25%. Multivariate analysis showed there was a statistically significant association between COVID-19 vaccination status and the severity of COVID-19 disease with an AOR 0.73 (95% CI 0.65-0.82) in the 1st dose, 0.38 (95% CI 0.35-0.41) at the 2nd dose, and 0.09 (95% CI 0.07-0.11) at the 3rd dose. But the magnitude of the association in the 2nd and 3rd was lower in the age group >60 years, the group with comorbidities, and the male sex group compared to the younger age group, those without comorbidities, and the female group. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. Government acceleration efforts and public awareness are needed to immediately increase the coverage of the booster dose of vaccination. Further prospective studies are needed to monitor the effectiveness and duration of vaccine protection as other new variants of the SARS-CoV-2 virus emerge.","PeriodicalId":32237,"journal":{"name":"Jurnal Ilmu Kesehatan Masyarakat","volume":"115 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association Between COVID-19 Vaccination Status With Severity of Confirmed COVID-19 Patients Period of January-July 2022 in Indonesia\",\"authors\":\"Eka Desi Purwanti, Sudarto Ronoatmojo\",\"doi\":\"10.26553/jikm.2023.14.1.13-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 vaccine is known to prevent infection, disease severity, and death from COVID-19. The emergence of a new variant of the SARS-CoV-2 would have an impact on the vaccine's effectiveness. This study aims to examine the association between COVID-19 vaccination status and the severity of COVID-19 symptoms during the dominating period of the Omicron variant. This is a cross-sectional study using secondary data from confirmed COVID-19 patients who were reported in the Ministry of Health's Online Hospital System for the period January–July 2022. Using logistic regression analysis, we calculated the adjusted odds ratio (AOR) of the association between vaccination status and the severity of COVID-19 symptoms. A total of 221,673 confirmed COVID-19 patient data were analyzed. The proportion of patients with severe-critical symptoms is 6.25%. Multivariate analysis showed there was a statistically significant association between COVID-19 vaccination status and the severity of COVID-19 disease with an AOR 0.73 (95% CI 0.65-0.82) in the 1st dose, 0.38 (95% CI 0.35-0.41) at the 2nd dose, and 0.09 (95% CI 0.07-0.11) at the 3rd dose. But the magnitude of the association in the 2nd and 3rd was lower in the age group >60 years, the group with comorbidities, and the male sex group compared to the younger age group, those without comorbidities, and the female group. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. Government acceleration efforts and public awareness are needed to immediately increase the coverage of the booster dose of vaccination. Further prospective studies are needed to monitor the effectiveness and duration of vaccine protection as other new variants of the SARS-CoV-2 virus emerge.\",\"PeriodicalId\":32237,\"journal\":{\"name\":\"Jurnal Ilmu Kesehatan Masyarakat\",\"volume\":\"115 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jurnal Ilmu Kesehatan Masyarakat\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26553/jikm.2023.14.1.13-26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Ilmu Kesehatan Masyarakat","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26553/jikm.2023.14.1.13-26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
已知COVID-19疫苗可以预防COVID-19的感染、疾病严重程度和死亡。SARS-CoV-2新变种的出现将对疫苗的有效性产生影响。本研究旨在研究在Omicron变异占主导地位期间,COVID-19疫苗接种状况与COVID-19症状严重程度之间的关系。这是一项横断面研究,使用了2022年1月至7月期间卫生部在线医院系统报告的COVID-19确诊患者的二手数据。通过logistic回归分析,我们计算了疫苗接种状况与COVID-19症状严重程度之间的校正优势比(AOR)。共分析了221673例新冠肺炎确诊患者的数据。重危重症患者比例为6.25%。多因素分析显示,COVID-19疫苗接种状况与COVID-19疾病严重程度之间存在统计学显著相关性,第一剂AOR为0.73 (95% CI 0.65 ~ 0.82),第二剂AOR为0.38 (95% CI 0.35 ~ 0.41),第三剂AOR为0.09 (95% CI 0.07 ~ 0.11)。但第二和第三阶段的相关性在>60岁年龄组、有合并症组和男性组中较低,与年轻年龄组、无合并症组和女性组相比。由此可见,接种COVID-19疫苗可降低COVID-19疾病严重程度的风险。由此可见,接种COVID-19疫苗可降低COVID-19疾病严重程度的风险。需要政府加快努力并提高公众意识,以立即增加疫苗接种加强剂的覆盖率。随着SARS-CoV-2病毒其他新变体的出现,需要进一步的前瞻性研究来监测疫苗保护的有效性和持续时间。
Association Between COVID-19 Vaccination Status With Severity of Confirmed COVID-19 Patients Period of January-July 2022 in Indonesia
The COVID-19 vaccine is known to prevent infection, disease severity, and death from COVID-19. The emergence of a new variant of the SARS-CoV-2 would have an impact on the vaccine's effectiveness. This study aims to examine the association between COVID-19 vaccination status and the severity of COVID-19 symptoms during the dominating period of the Omicron variant. This is a cross-sectional study using secondary data from confirmed COVID-19 patients who were reported in the Ministry of Health's Online Hospital System for the period January–July 2022. Using logistic regression analysis, we calculated the adjusted odds ratio (AOR) of the association between vaccination status and the severity of COVID-19 symptoms. A total of 221,673 confirmed COVID-19 patient data were analyzed. The proportion of patients with severe-critical symptoms is 6.25%. Multivariate analysis showed there was a statistically significant association between COVID-19 vaccination status and the severity of COVID-19 disease with an AOR 0.73 (95% CI 0.65-0.82) in the 1st dose, 0.38 (95% CI 0.35-0.41) at the 2nd dose, and 0.09 (95% CI 0.07-0.11) at the 3rd dose. But the magnitude of the association in the 2nd and 3rd was lower in the age group >60 years, the group with comorbidities, and the male sex group compared to the younger age group, those without comorbidities, and the female group. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. It can be concluded that COVID-19 vaccination reduces the risk of severity of COVID-19 disease. Government acceleration efforts and public awareness are needed to immediately increase the coverage of the booster dose of vaccination. Further prospective studies are needed to monitor the effectiveness and duration of vaccine protection as other new variants of the SARS-CoV-2 virus emerge.